| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Antiangiogenic agents should be integrated into the standard treatment for patients with ovarian cancer
|
Burger, R.A.
|
|
|
22 |
S8 |
p. viii65-viii68
|
article
|
| 2 |
Designing early detection programs for ovarian cancer
|
Urban, N.
|
|
|
22 |
S8 |
p. viii16-viii18
|
article
|
| 3 |
Dose-dense therapy is of benefit in primary treatment of ovarian cancer: contra
|
van der Burg, M.E.L.
|
|
|
22 |
S8 |
p. viii33-viii39
|
article
|
| 4 |
Dose-dense therapy is of benefit in primary treatment of ovarian cancer? In favor
|
Katsumata, N.
|
|
|
22 |
S8 |
p. viii29-viii32
|
article
|
| 5 |
Editorial board
|
|
|
|
22 |
S8 |
p. ii
|
article
|
| 6 |
Follow-up with CA125 after primary therapy of advanced ovarian cancer has major implications for treatment outcome and trial performances and should not be routinely performed
|
Rustin, G.J.S.
|
|
|
22 |
S8 |
p. viii45-viii48
|
article
|
| 7 |
Follow-up with CA125 after primary therapy of advanced ovarian cancer: in favor of continuing to prescribe CA125 during follow-up
|
Pignata, S.
|
|
|
22 |
S8 |
p. viii40-viii44
|
article
|
| 8 |
Molecular approaches to personalizing management of ovarian cancer
|
Bast Jr, R.C.
|
|
|
22 |
S8 |
p. viii5-viii15
|
article
|
| 9 |
New drugs for ovarian cancer
|
Bell-McGuinn, K.
|
|
|
22 |
S8 |
p. viii77-viii82
|
article
|
| 10 |
Optimal assessment of response in ovarian cancer
|
Eisenhauer, E.A.
|
|
|
22 |
S8 |
p. viii49-viii51
|
article
|
| 11 |
Quality control in ovarian cancer surgery
|
Hacker, N.F.
|
|
|
22 |
S8 |
p. viii19-viii22
|
article
|
| 12 |
Table of Contents
|
|
|
|
22 |
S8 |
p. iii
|
article
|
| 13 |
The use of bevacizumab in the management of ovarian cancer: an argument for single-agent rather than combination therapy
|
Markman, M.
|
|
|
22 |
S8 |
p. viii69-viii71
|
article
|
| 14 |
To predict or not to predict? The dilemma of predicting the risk of suboptimal cytoreduction in ovarian cancer
|
Kang, S.
|
|
|
22 |
S8 |
p. viii23-viii28
|
article
|
| 15 |
Update of randomized trials in first-line treatment
|
Bookman, Michael A.
|
|
|
22 |
S8 |
p. viii52-viii60
|
article
|
| 16 |
Update of randomized trials in recurrent disease
|
Pujade-Lauraine, E.
|
|
|
22 |
S8 |
p. viii61-viii64
|
article
|
| 17 |
Update on PARP1 inhibitors in ovarian cancer
|
Sessa, C.
|
|
|
22 |
S8 |
p. viii72-viii76
|
article
|
Journal description